NEW DELHI New Delhi: Bengaluru-based cell and gene therapy start-up Immunil Therapeutics on Monday launched the country's first personalized and precision therapy CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) in adults. Announced the launch of Quartemi.

B-cell non-Hodgkin lymphoma (B-NHL) is a type of blood cancer that affects B cells in the lymphatic system. B-NHL is the most common type of non-Hodgkin lymphoma (NHL) in India, accounting for 80-85 percent of all cases. Adults with relapsed, relapsed or refractory B-NHL are eligible for chemotherapy approved by the Indian regulator Central Drugs Standard Control Organization (CDSCO). Provides a personalized therapy to patients. It is also licensed by Hospital Clínic de Barcelona (HCB), Spain, a globally renowned institution at the forefront of cell therapy innovation.

Developed indigenously in Bengaluru, Quertemy (varnimcarbatazine autoleucel – IMN-003A) uses a patient's immune cells to target and eliminate cancer, providing new hope for people battling aggressive blood cancers . It has shown the ability to provide lasting remission of relapsed and refractory NHL, even when conventional treatments, including chemotherapy, prove ineffective.

Notably, its price is one-tenth the price of a similar product in the US, the company said. “Since Immunil's founding in 2019, our mission has been to provide affordable and innovative, life-saving therapies for cancers that would otherwise be difficult to treat.” are inaccessible,” Kiran Mazumdar-Shaw, board director and co-founder, Immunil Therapeutics.

“With our lead CAR T-cell therapy, Quartemy, we aim to transform cancer treatment in India by providing globally advanced, personalized treatments at an affordable cost,” said Majumdar-Shaw. Launched in 2019 Immunil begins trials in 2022 on India's first CAR T-cell therapy trial for a novel autologous T-cell therapy in patients with relapsed/refractory B cell malignancy Stands for CD19-directed CAR-T cell therapy. The trial was conducted in various hospitals including PGIMER in Chandigarh and other hospitals in Bengaluru and Chennai.

CD19-directed, genetically modified autologous chimeric antigen receptor T-cell immunotherapy involves modifying a patient's T-cells to specifically target and destroy cancer cells. Data from clinical trials in India and Spain show that the safety and efficacy of Qartemi is similar to that of USFDA-approved CAR T-cell therapies. The launch of CAR-T cell therapy is an important moment in the fight against cancer in India. By combining world-class research CAR-T cell therapy with indigenous manufacturing, we are giving new hope to patients facing aggressive blood cancers. Are.”